AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05338684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colour doppler,MSCT,MRI
Description: ultrasound/color duplex at Jugular veins \& carotid and vertebral arteries first ,then MSCT/CTA mainly with relation of neck \& Bain arteries to the bone of the skull in 6 mm cuts and/or MRI/MRA/MRV by standardized multi-parametric MR protocol will be implemented for all patients. All sequences will be acquired on a 1.5T MR scanner.
Study NCT05939453 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Light
Description: Sham treatment will be provided from a light box at a distance of at least 70cm but no greater than 90cm.
Study NCT05939453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: Bright Light Therapy will be provided using light box with an artificial full spectrum lamp at a distance of at least 70cm but no greater than 90cm.
Study NCT04271878 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
Description: 1. HUTT with Normal Breathing in Room Air (No gas interventions will be applied)~2. HUTT with Normal Breathing and ETCO2 clamped at baseline levels~3. HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg )~4. HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg)~5. HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied~6. HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels.
Study NCT06016309 — intervention group
Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention.
Study NCT05910684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aegis CDM Test and Educational Materials
Description: The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.
Study NCT05409625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral Scanner (TRIOS 4, 3Shape TRIOS A/S, Copenhagen, Denmark)
Description: Intraoral scanner which is able to generate a 3D-model of the teeth and is being used for caries detection.
Study NCT05409625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral camera (DIAGNOcam, KaVo, Biberach, Germany, software version 3.0.1/2.9.1)
Description: Intraoral camera used for caries detection in the occlusal and proximal surfaces.
Study NCT05409625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-ray device (X-ray device SOREDEX, MINRAY®; Image plates VistaScan; Image plate scanner VistaScan Mini View, Dürr Dental)
Description: X-ray device used for caries detection. Two radiographs (bitewings) are taken, one in each side.
Study NCT05409625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral cleaning
Description: Removal of tartar and plaque. Tartar removal done at baseline and the fifth visit, but only on selected teeth at the second, third and fourth visit. Regular cleaning with a toothbrush done at all visits.
Study NCT06296069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exergame-based cognitive-motor training on an unstable surface
Description: The intervention group will receive an exergame-based cognitive-sensorimotor intervention on an unstable surface (by placing the exergame device (Senso) on an unstable surface).~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces. For the labile condition, the Senso is mounted on steel balls, allowing the platform to swing freely along the horizontal plane. There is no movement induced by the platform itself. Sway is only induced when the participant steps and shifts the center of pressure. The degree of instability and movement of the platform can be adjusted by inducing a dampening. The dampening can be set manually, either to on or off. When damping is on, the movement can be reduced by predefined percentages. The maximum displacement of the platform is thereby 100 mm to each side.
Study NCT06296069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exergame-based cognitive-motor training on an stable surface
Description: The control group will receive an exergame-based cognitive-motor intervention on an stable surface using the exergame device Senso.~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces.
Study NCT05665634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concurrent transcranial magnetic stimulation and electroencephalogram
Description: Single and paired-pulse TMS will be applied to 5 different brain regions during simultaneous recording of EEG. Paired-pulse stimulations will have either 3 ms or 11 ms between pulses, to stimulate cortical inhibition and excitation respectively. Stimulation intensity for single-pulse stimulation blocks will be 120% of the resting motor threshold (RMT). For paired-pulse blocks, the conditioning (first) pulse will be delivered at a stimulation intensity of 80% RMT, and the test (second) pulse will be delivered at 120% RMT. Each test block will consist of 60 TMS trials and will last for 5 minutes. Order of test blocks will be pseudo-randomized across participants. Out of 5 stimulation sites, 3 will be determined based on individual's own brain anatomy and resting state connectivity. These 3 regions will be stimulated using all 3 TMS protocols. The other two regions will be determined based on the literature and only be targeted using the single pulse TMS protocol.
Study NCT06346717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knee Prosthesis-M mobile application service
Description: In the early phase of mobile application development, qualitative interviews will be conducted with patients with total knee arthroplasty (TKA) experience regarding their own surgery experiences. A training booklet for Knee prosthesis-M will be created, taking into account the literature and patient feedback. Then, the Knee prosthesis-M application design will be completed. One day before surgery; Written consent will be obtained from patients who meet the criteria via an Informed Consent Form. Patients in the intervention group will access the Knee Prosthesis-M application from their smartphones and will be asked to use it actively for 6 weeks, starting from the 1st day of the surgery. Mobile application-supported care will be provided to the patients by sending information, warning and reminder messages to the patients for 6 weeks.
Study NCT05447052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-MIMICS 3D Stent
Description: Bio-MIMICS Stent implantation
Study NCT05447052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Innova Stent
Description: Innova Stent implantation
Study NCT03770546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion Injection
Description: Per the manufacturer, this is considered an injection of tissue/organic matter.
Study NCT03770546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone injection
Description: Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
Study NCT05176288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Taken Orally
Study NCT05176288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Taken Orally
Study NCT05176288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Intravenous infusion
Study NCT04596267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: 8.9mg Pitolisant for 5 days
Study NCT04596267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert ingredients
Study NCT06124287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR Enterography (MRE)
Description: MRI scan
Study NCT05060068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine (low dose)
Description: Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
Study NCT05060068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
Study NCT05060068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine (high dose)
Description: Patients in the high-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
Study NCT05235230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product (T) 25 mg Film Coated Tablets
Description: Film Coated Tablets products containing 25 mg Quetiapine
Study NCT05235230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product (R) 25 mg Film Coated Tablets
Description: Reference product (R) 25 mg Film Coated Tablets
Study NCT06035159 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: online psychotherapy
Description: 6 modules
Study NCT05168202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95251
Description: Specified dose on specified days
Study NCT05168202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Specified dose on specified days
Study NCT05168202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Specified dose on specified days
Study NCT06446089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THP: cognitive behavior therapy and behavioral activation
Description: The adapted THP takes into account cultural and linguistic characteristics of the participants. Participants will be invited to complete three modules on an Android based app on their mobile, populated with information and activities from the adapted THP.
Study NCT06070454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginitis panel
Description: vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida
Study NCT06582901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) plus the neuropsychological educational approach to cognitive remediation (NEAR) model and an Enhanced - Treatment as Usual (E-TAU)
Description: Psychosocial interactions computer-based cognitive training (CT) administered in a group setting that includes the Neuropsychological Educational Approach to Cognitive Remediation (NEAR) model:
Study NCT06582901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced - Treatment as Usual
Description: The Enhanced-Treatment as Usual (E-TAU) sessions are delivered in a group therapy format and guided by the principles of Cognitive Behavioral Therapy (CBT). Participants learn to develop coping skills and are educated on how to improve distortions to reduce anxiety and depression.
Study NCT04799964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Diverter (Tonbridge)
Description: The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
Study NCT04799964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tubridge (MicroPort)
Description: Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.
Study NCT05964842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
Study NCT05964842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call
Description: Participants in this arm will receive three phone call reminders. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
Study NCT05964842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile money incentive
Description: Once participants in the study arms with mobile money complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money.
Study NCT04488679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: direct pulp capping
Description: teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
Study NCT04488679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: direct pulp capping
Description: teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
Study NCT06540261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7913
Description: Specified dose on specified days
Study NCT06540261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days
Study NCT06540261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days
Study NCT06540261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days
Study NCT06540261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: Specified dose on specified days
Study NCT06540261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days
Study NCT06540261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days
Study NCT05796583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Pulsed Shortwave Treatment
Description: Application of 8 days of nonthermal, pulsed shortwave (radiofrequency) therapy with Endonovo Therapeutics SofPulse
Study NCT05796583 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Application of 8 days of a nonfunctional sham device
Study NCT05277766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Nal-IRI
Description: Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.
Study NCT06472427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normoxic recovery and placebo (NPL)
Description: Altitude: sea level Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
Study NCT06472427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normoxic recovery and ketones (NKE)
Description: Altitude: sea level Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
Study NCT06472427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypoxic recovery and placebo (HPL)
Description: Altitude: 3,000m (simulated) Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
Study NCT06472427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypoxic recovery and ketones (HKE)
Description: Altitude: 3,000m (simulated) Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
Study NCT05444855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Leader Model
Description: Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liaison via text messages throughout the study.
Study NCT05258721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClōSYS® Sensitive Fluoride Toothpaste
Description: ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.
Study NCT05258721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ClōSYS® Sensitive Rinse
Description: ClōSYS® Sensitive Rinse is a cosmetic product containing 0.1% stabilized chlorine dioxide.
Study NCT05569044 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No intervention
Study NCT05569044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution
Description: Participants will be administered ORS during one of the study visits
Study NCT05569044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will be administered water during one of the study visits
Study NCT06300697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data and biospecimen collection
Description: Enrolled participants will have health-related information and blood specimens collected.
Study NCT06300697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies
Description: Participants will be asked to provide one or two skin biopsies (days 1 and 2) from the forearm, unless the participant is a healthy child (no food allergy and no atopic dermatitis), in which case there will be no skin biopsy.
Study NCT06300697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral Food Challenge (OFC) procedures
Description: Participants will have the choice of consenting to an OFC (approximately 2-4 hours) to peanut, tree nut, egg, milk, or sesame. If there is no allergy history, the study team will conduct an oral food challenge to one of the choices. The OFC will occur in the clinical research area. and done the same as a clinical care OFC. A transepidermal water loss monitor will be applied to participant's arm with a sticky pad and will stay on the arm for the challenge. Food doses will be given in small amounts that increase in size up to a defined single serving of the food based upon the participants age/size. The OFC will proceed until a full dose is consumed without symptoms, or until anaphylaxis occurs. Depending upon the participant's reaction to the oral food challenge, the participant may be requested to return the next day for a research visit that would take less than an hour. The 24-hour post oral food challenge visit will include an interview to assess condition and a blood sample.
Study NCT05058339 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT05328102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plamotamab
Description: Biological
Study NCT05328102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Biological
Study NCT05328102 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tafasitamab
Description: Biological
Study NCT05328102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Drug
Study NCT05328102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Drug
Study NCT06492122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225Ac]Ac-FL-020
Description: \[225Ac\]Ac-FL-020 injected intravenously
Study NCT06492122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blood samples for PK
Description: Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.
Study NCT05516446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB for de Novo Lesions
Description: The surface of the SeQuent® Please NEO balloon is coated with Paclitaxel at a concentration of 3 μg Paclitaxel per mm² of balloon surface. The matrix composed of Paclitaxel and Iopromide (Paccocath technology) allows homogeneous release of the active ingredient through the vessel surface.
Study NCT05516446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DES for de Novo Lesions
Description: The latest generation DES : everolimus-eluting platinum-chromium alloy coronary stent system (Promus Premier, Promus Elite)